Skip to Content

Incyte Corp - Stock Quote INCY

Rating as of

Morningstar's Incyte Corp Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Incyte's Jakafi and Growing Oncology and Dermatology Portfolio Support a Narrow Moat

Karen Andersen, CFA Sector Strategist

Business Strategy and Outlook

| Karen Andersen, CFA |

Incyte's lead drug, Jakafi, initially gained traction in 2011 as the only drug approved for severe myelofibrosis, a rare blood disorder. Jakafi's stronghold of the MF market is likely to continue, although new drugs are entering the market for subsets of the population. Incyte expanded Jakafi’s label to polycythemia vera (2014), steroid refractory acute graft versus host disease (2019), and chronic GvHD (2021) should together push peak U.S. sales to nearly $3.5 billion.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics - INCY

Incyte Corp's Company Profile

Business Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

1801 Augustine Cut-Off
Wilmington, DE, 19803
T +1 302 498-6700
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type Aggressive Growth
Employees 2,094

Incyte Corp's Related News